Eli Lilly & Co. announced positive results from its Phase 3 SUMMIT trial evaluating tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The trial revealed that tirzepatide reduced heart failure outcomes by 38% compared to placebo, significantly improved heart failure symptoms, and led to a 15.7% weight loss over 52 weeks. These findings highlight tirzepatide's potential to address the significant unmet need in treating HFpEF, particularly in patients with concurrent obesity.
Lilly plans to submit the results for regulatory approval later this year.
